

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/991,335	11/13/2001	Richard Wisniewski	2035.748	4294
7590 12/02/2003			EXAMINER	
Nicholas Mesiti, Esq. HESLIN ROTHENBERG FARLEY & MESITI P.C. 5 Columbia Circle Albany, NY 12203-5160			BEISNER, WILLIAM H	
			ART UNIT	PAPER NUMBER
			1744	·
			DATE MAILED: 12/02/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

		CP/I		
	Application No.	pplicant(s)		
Office Astion Commons	09/991,335	WISNIEWSKI, RICHARD		
Office Action Summary	Examiner	Art Unit		
	William H. Beisner	1744		
The MAILING DATE of this communication Period for Reply	appears on the cover sheet with	the correspondence address		
A SHORTENED STATUTORY PERIOD FOR RE THE MAILING DATE OF THIS COMMUNICATIO - Extensions of time may be available under the provisions of 37 CFF after SIX (6) MONTHS from the mailing date of this communication - If the period for reply specified above is less than thirty (30) days, a - If NO period for reply is specified above, the maximum statutory per - Failure to reply within the set or extended period for reply will, by stream of the provided period for reply will, by stream of the provided patent term adjustment. See 37 CFR 1.704(b). Status	N. R 1.136(a). In no event, however, may a replant of thirty (a reply within the statutory minimum of thirty (a riod will apply and will expire SIX (6) MONTH atute, cause the application to become ABAN	ly be timely filed 30) days will be considered timely. IS from the mailing date of this communication. IDONED (35 U.S.C. § 133).		
1) Responsive to communication(s) filed on 3.	/15/02; 2/12/03; and 7/14/03.			
2a)☐ This action is FINAL . 2b)⊠ T	his action is non-final.			
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.				
Disposition of Claims				
4) Claim(s) <u>1-54</u> is/are pending in the applicat 4a) Of the above claim(s) is/are without 5) Claim(s) is/are allowed. 6) Claim(s) <u>1-54</u> is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction an	drawn from consideration.			
Application Papers		·		
9) The specification is objected to by the Exam 10) The drawing(s) filed on 15 March 2002 is/ar Applicant may not request that any objection to a Replacement drawing sheet(s) including the con 11) The oath or declaration is objected to by the Priority under 35 U.S.C. §§ 119 and 120	e: a)⊠ accepted or b)⊡ object the drawing(s) be held in abeyance rection is required if the drawing(s)	e. See 37 CFR 1.85(a). is objected to. See 37 CFR 1.121(d).		
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).				
a) All b) Some * c) None of: 1. Certified copies of the priority docume. 2. Certified copies of the priority docume. 3. Copies of the certified copies of the property application from the International Bure. * See the attached detailed Office action for a since a specific reference was included in the 37 CFR 1.78. a) The translation of the foreign language. 14) Acknowledgment is made of a claim for dome of the foreign language.	ents have been received in Appropriority documents have been receau (PCT Rule 17.2(a)). list of the certified copies not relestic priority under 35 U.S.C. § first sentence of the specification provisional application has bee estic priority under 35 U.S.C. §§	ceived in this National Stage ceived. 119(e) (to a provisional application) on or in an Application Data Sheet. n received. 120 and/or 121 since a specific		
Attachment(s)				
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 	5) Notice of Info	nmary (PTO-413) Paper No(s) rmal Patent Application (PTO-152)		

Application/Control Number: 09/991,335 Page 2

Art Unit: 1744

DETAILED ACTION

Information Disclosure Statement

1. The information disclosure statements filed 13 Nov. 2001 and 24 Feb. 2002 have been considered and made of record.

Priority

2. The references to the continuing applications listed in the first line of the specification needs to be updated so as to include the current status of these cases as being patented, including their patent numbers.

Oath/Declaration

3. The oath or declaration is defective. A new oath or declaration in compliance with 37 CFR 1.67(a) identifying this application by application number and filing date is required. See MPEP §§ 602.01 and 602.02.

The oath or declaration is defective because:

The specification to which the oath or declaration is directed has not been adequately identified. See MPEP § 601.01(a).

The instant declaration or oath identifies the specification as that of parent application 09/003,283. While the instant application may claim benefit and include common subject matter with respect to application 09/003,283, the specification of the instant application is not identical to that of 09/003,283. As a result, identification of the instant specification to be that of 09/003,283 is erroneous.

Application/Control Number: 09/991,335

Art Unit: 1744

Double Patenting

Page 3

4. A rejection based on double patenting of the "same invention" type finds its support in the language of 35 U.S.C. 101 which states that "whoever invents or discovers any new and useful process ... may obtain a patent therefor ..." (Emphasis added). Thus, the term "same invention," in this context, means an invention drawn to identical subject matter. See *Miller v. Eagle Mfg. Co.*, 151 U.S. 186 (1894); *In re Ockert*, 245 F.2d 467, 114 USPQ 330 (CCPA 1957); and *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970).

A statutory type (35 U.S.C. 101) double patenting rejection can be overcome by canceling or amending the conflicting claims so they are no longer coextensive in scope. The filing of a terminal disclaimer <u>cannot</u> overcome a double patenting rejection based upon 35 U.S.C. 101.

5. Claims 13-40 are rejected under 35 U.S.C. 101 as claiming the same invention as that of claims 13-40 of prior U.S. Patent No. 6,337,205. This is a double patenting rejection.

Claims 13-40 of the instant application are of the same scope as claims 13-40 of Patent No. '205 even though the patent claim language recited "coupled to a distal end of the body" and the instant claims recited "coupled to at least one distal end". Both sets of claims result in at least one nucleating structure, coupled to **one** distal end of the body. The patented claims do not preclude the presence of additional nucleating structures coupled to additional distal ends which is also implied by the language of the instant claims "at least one distal end".

6. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Application/Control Number: 09/991,335

Art Unit: 1744

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Page 4

7. Claims 1-12 and 41-54 are rejected under the judicially created doctrine of obviousnesstype double patenting as being unpatentable over claims 1-40 of U.S. Patent No. 6,337,205. Although the conflicting claims are not identical, they are not patentably distinct from each other because instant claims 1-12 and 45-51 are anticipated by claims 1-12 of the patent No. '205 even though the patent claims include the additional language "surrounded by the cryopreservation fluid". With respect to claims 41 and 44, the use of plural nucleating structures would have been obvious based merely on the number of fronts employed and/to increase the heat transfer surface area of the nucleating zone of the body. With respect to claims 42 and 43, it would have been obvious to one of ordinary skill in the art to position the body such that the nucleating structure contacts the cryopreservation fluid, if not, the desired freezing would not be obtained. With respect to claims 52-54, while the patented claims are silent as to the direction of the oblong cross-section of the vial, it would have been obvious to provide a vial with the claimed crosssection when positioning the vial in a cryogenic flow of fluid that flows horizontally within the holding chamber so as to maintain the desired nucleating front.

Allowable Subject Matter

8. If a terminal disclaimer is filed and the identical claims are canceled, the remaining claims would be allowable for the reasons set forth below:

Application/Control Number: 09/991,335

Art Unit: 1744

The following is a statement of reasons for the indication of allowable subject matter: 9.

While the prior art of record discloses cryopreservation vials constructed of a cryogenically

stable material and at least one nucleating structure associated with the vial (See the references

of Strasser and Schilling), the prior art of record fails to teach or fairly suggest a vial of an

oblong cross-section having a proximal and distal ends wherein at least one nucleating structure

is provided on a distal end of the vial.

Conclusion

Any inquiry concerning this communication or earlier communications from the 10.

examiner should be directed to William H. Beisner whose telephone number is 703-308-4006

(571-272-1269 after 12/16/03). The examiner can normally be reached on Tues. to Fri. and alt.

Mon. from 6:40am to 4:10pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Robert J. Warden can be reached on 703-308-2920 (571-272-1281 after 12/16/03).

The fax phone number for the organization where this application or proceeding is assigned is

703-872-9310.

Any inquiry of a general nature or relating to the status of this application or proceeding

should be directed to the receptionist whose telephone number is 703-308-0661.

Primary Examiner

Page 5

Art Unit 1744

WHB